Amino-01 (July 2018)

Amino-01 (JULY 2018) 180124 AA SPIFAN SLV Appendices A-I

FOR ERP USE ONLY DO NOT DISTRIBUTE

Single Laboratory Validation Report for Total Amino Acids by UHPLC-UV in Infant Formulas and Adult Nutritionals -– APPENDICES (A to I) Appendix D : repeatability data obtained with the SPIFAN II SLV kit products, color-coded with respect to performance requirement values.

SPIFAN II SLV kit product

Analyte 1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19

His

0.7% 0.4% 1.2%

3.7% 1.9% 0.5% 0.8% 0.9% 2.0% 1.1% 1.4% 1.2% 3.0% 1.2% 2.0% 1.4% 0.0% 1.6% 0.8%

Tau N/A N/A N/A N/A N/A

1.2% 1.4% 1.8% 2.3% 1.3%

N/A

1.0% 1.9% 1.7% 2.8% 1.8% 1.6% 2.2% 2.5%

Repeatability data were obtained with robust statistics. For each analyte/matrix pair, the repeatability was compared with the corresponding performance requirement*. 99% of the values are within the requirements (green) and 2% could not be attributed (blank values for taurine). * updated version proposed by the amino acid working group to be reviewed by the stakeholder panel during the August 2018 annual meeting. Ser 0.7% 0.6% 0.2% 0.7% 0.6% 1.0% 1.0% 0.7% 1.0% 0.8% 0.4% 0.8% 2.9% 1.9% 2.0% 0.5% 0.7% 1.5% 1.5% Arg 0.5% 0.4% 0.8% 1.9% 1.5% 1.3% 1.4% 1.1% 1.5% 1.3% 1.9% 1.6% 1.7% 1.7% 1.2% 1.3% 1.5% 1.6% 2.0% Gly 0.6% 1.1% 1.0% 1.7% 1.9% 0.4% 1.2% 1.2% 1.4% 0.4% 1.0% 1.0% 1.2% 0.7% 0.5% 0.5% 0.0% 1.0% 1.5% Asp 0.9% 1.5% 1.4% 2.3% 0.7% 0.5% 0.4% 0.7% 0.8% 1.2% 0.9% 0.4% 1.7% 0.6% 1.8% 0.5% 0.7% 0.6% 1.1% Glu 0.6% 0.6% 0.6% 2.0% 1.0% 0.5% 0.3% 0.8% 0.6% 0.7% 0.5% 0.6% 1.4% 0.4% 0.5% 0.7% 0.5% 0.6% 1.6% Thr 0.3% 0.6% 0.4% 0.6% 0.6% 0.7% 0.8% 0.7% 0.7% 1.1% 0.4% 0.5% 1.6% 1.2% 1.3% 0.4% 0.6% 1.0% 1.3% Ala 0.5% 0.9% 1.2% 1.7% 0.8% 0.7% 0.3% 0.8% 0.7% 0.7% 0.4% 0.5% 1.6% 0.4% 0.5% 0.3% 0.8% 0.7% 1.3% Pro 0.4% 0.3% 0.5% 1.4% 0.9% 0.8% 0.5% 1.3% 0.6% 0.7% 0.8% 0.4% 1.2% 0.6% 0.7% 0.4% 0.0% 0.8% 1.0% Lys 1.0% 0.6% 0.5% 3.0% 0.9% 1.0% 0.7% 1.4% 1.2% 0.5% 1.0% 1.3% 1.9% 0.9% 0.9% 0.7% 0.9% 0.9% 1.5% Tyr 0.5% 1.6% 1.6% 1.8% 0.9% 0.8% 0.6% 1.5% 1.5% 1.7% 1.3% 0.6% 2.4% 0.3% 1.0% 1.3% 1.9% 1.2% 1.0% xCys 1.0% 0.5% 0.9% 3.1% 0.0% 1.6% 1.2% 1.4% 1.1% 2.1% 1.7% 1.3% 3.9% 0.7% 0.6% 2.9% 0.0% 0.0% 2.1% Met 0.3% 0.7% 0.8% 1.6% 1.7% 1.5% 1.4% 1.0% 1.1% 1.0% 1.1% 1.3% 0.7% 0.8% 0.6% 1.0% 0.0% 1.5% 2.1% Val 2.0% 0.3% 1.1% 1.5% 2.6% 0.8% 1.2% 1.3% 2.0% 1.7% 0.7% 0.8% 0.9% 1.8% 1.6% 3.4% 1.8% 1.9% 1.1% Ile 1.7% 0.3% 1.3% 1.9% 3.4% 0.9% 0.7% 1.1% 2.2% 2.1% 0.7% 0.8% 1.2% 2.2% 2.3% 3.2% 2.5% 2.3% 1.7% Leu 0.5% 0.3% 0.5% 1.4% 1.0% 0.9% 0.5% 0.7% 1.2% 0.5% 0.5% 0.5% 1.0% 0.6% 0.7% 0.9% 0.4% 0.8% 1.0% Phe 0.7% 0.7% 1.2% 2.0% 1.8% 0.6% 1.1% 1.0% 1.9% 1.1% 0.8% 1.1% 1.2% 0.5% 1.1% 0.7% 1.8% 0.8% 0.9%

Jaudzems, Guthrie, Lahrichi, and Fuerer – January 2018

page 4/22